Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.04
+1.040.89%
Volume:27.24K
Turnover:3.22M
Market Cap:9.82B
PE:-36.75
High:119.63
Open:118.40
Low:117.32
Close:117.00
52wk High:130.05
52wk Low:45.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.86
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.50
PE(LYR):-31.99

Loading ...

BRIEF-Kymera Therapeutics Q1 EPS USD -0.71

Reuters
·
Apr 30

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

GlobeNewswire
·
Apr 30

Kymera CEO Nello Mainolfi disposes of common shares worth $2,430,898.39

Reuters
·
Apr 30

Kymera director Bruce Booth disposes of common shares worth $538,687

Reuters
·
Apr 25

Kymera COO Jeremy Chadwick disposes 300 shares for $27,000

Reuters
·
Apr 25

Kymera Therapeutics to report first-quarter financial results, host webcast call

Reuters
·
Apr 23

Kymera COO Jeremy Chadwick disposes of USD 589,510 Kymera Therapeutics shares

Reuters
·
Apr 17

Kymera Therapeutics Chief Business Officer Noah Goodman sells 1,347 shares for $121,230

Reuters
·
Apr 17

Kymera director Bruce Booth disposes of common shares worth $836,290.08

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

FDA grants fast track designation to Kymera Therapeutics KT-621

TIPRANKS
·
Apr 13

Kymera says FDA grants Fast Track designation for KT-621 in eosinophilic asthma

Reuters
·
Apr 13

Kymera Therapeutics Inc - KT-621 Broaden2 Phase 2B Atopic Dermatitis Trial Ongoing, Data Expected by Mid-2027

THOMSON REUTERS
·
Apr 13

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma

THOMSON REUTERS
·
Apr 13

Kymera CBO Noah Goodman disposes of common shares worth $893,260.62

Reuters
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

BUZZ-Kymera rises as Gilead pays $45 million for experimental cancer drug

Reuters
·
Apr 09

Kymera Therapeutics Inc - Gilead to Advance KT-200 Into Ind-Enabling Studies for 2027 Ind Filing

THOMSON REUTERS
·
Apr 09

Kymera Therapeutics Inc - to Receive $45 Mln Milestone Payment From Gilead for KT-200 Option

THOMSON REUTERS
·
Apr 09